IP Library Granted Patent US 8,685,979
Granted Patent B2
US 8,685,979 · App. 12/864,481 · Granted Apr 1, 2014

Oligomer-diarylpiperazine conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,979
App. No.
12/864,481
Granted
Apr 1, 2014
Kind
B2
Abstract

The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds.

Claims (13)

1. A compound having a structure selected from the group consisting of

wherein, in each structure, R 3 is either H or CH 3 , R 5 is either H or CH 3 , X is a spacer moiety, and POLY is a water-soluble, non-peptidic oligomer.

2. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is a poly(alkylene oxide).

3. The compound of claim 2 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).

4. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer has between 1 and 30 monomers.

5. The compound of claim 4 , wherein the water-soluble, non-peptidic oligomer has between 1 and 10 monomers.

6. The compound of claim 2 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

7. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is covalently attached via a stable linkage.

8. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is covalently attached via a degradable linkage.

9. The compound of claim 1 , wherein X is an oxygen.

10. The compound of claim 1 , wherein X is an ester.

11. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.

12. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2011
From: REN, ZHONGXU; RIGGS-SAUTHIER, JENNIFER
To: NEKTAR THERAPEUTICS
Reel/Frame 027169/0069 →